Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2544-2553

  Gould, Travis J ^a,b   Vu, Trang T ^a,b   Stafford, Alan R ^b,c   Dwivedi, Dhruva J ^b   Kim, Paul Y ^b,c   Fox Robichaud, Alison E ^b,c   Weitz, Jeffrey I ^b,c   Liaw, Patricia C ^b,c  

^a Department of Medical Sciences ^*  (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Fibrinolysis; plasminogen activator inhibitor 1; sepsis; tissue plasminogen activator

Indexed keywords

CELL DNA; CELL FREE DNA; DEOXYRIBONUCLEASE; FIBRIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; DNA; FIBRINOGEN; PLASMINOGEN; PROTEIN BINDING;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOSIS; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; SCANNING ELECTRON MICROSCOPY; SEPSIS; SURFACE PLASMON RESONANCE; VIRUS INFECTION; AGED; BLOOD; CASE CONTROL STUDY; EXTRACELLULAR TRAP; GENETICS; METABOLISM; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CASE-CONTROL STUDIES; DNA; EXTRACELLULAR TRAPS; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRINOGEN; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PLASMINOGEN; PROTEIN BINDING; SEPSIS; SURFACE PLASMON RESONANCE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84948114834     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306035     Document Type: Article

References (60)

1. Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem. 2003;49:562-569.
2. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207-214. doi: 10.1056/NEJM199901213400307.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150. doi: 10.1056/NEJMra021333.
4. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lämmle B, Hack CE. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med. 2003;31:1947-1951. doi: 10.1097/01. CCM.0000074719.40109.95.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
6. Margraf S, Lögters T, Reipen J, Altrichter J, Scholz M, Windolf J. Neutrophil-derived circulating free DNA (cf-DNA/NETs): a potential prognostic marker for posttraumatic development of inflammatory second hit and sepsis. Shock. 2008;30:352-358. doi: 10.1097/SHK.0b013e31816a6bb1.
7. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, Cook DJ, Fox-Robichaud AE, Liaw PC; Canadian Critical Care Translational Biology Group. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care. 2012;16:R151. doi: 10.1186/cc11466.
8. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003;16:43-47. doi: 10.1023/B:T HRO.0000014592.27892.11.
9. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med. 2010;38(2 Suppl):S35-S42. doi: 10.1097/CCM.0b013e3181c9e31d.
10. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290-295. doi: 10.1016/j. thromres.2011.10.013.
11. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-1316. doi: 10.1001/jama.2014.2637.
12. Ulloa L, Brunner M, Ramos L, Deitch EA. Scientific and clinical challenges in sepsis. Curr Pharm Des. 2009;15:1918-1935.
13. The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup, Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228. doi: 10.1007/s00134-012-2769-8.
14. Yipp BG, Kubes P. NETosis: how vital is it Blood. 2013;122:2784-2794. doi: 10.1182/blood-2013-04-457671.
15. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535. doi: 10.1126/science.1092385.
16. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1777-1783. doi: 10.1161/ATVBAHA.111.242859.
17. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313:139-142.
18. Atamaniuk J, Kopecky C, Skoupy S, Saëmann MD, Weichhart T. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol Dial Transplant. 2012;27:902-905. doi: 10.1093/ndt/gfr695.
19. Jiang N, Reich CF 3rd, Pisetsky DS. Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood. 2003;102:2243-2250. doi: 10.1182/blood-2002-10-3312.
20. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880-15885. doi: 10.1073/pnas.1005743107.
21. Choi JJ, Reich CF 3rd, Pisetsky DS. Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. Scand J Immunol. 2004;60:159-166. doi: 10.1111/j.0300-9475.2004.01470.x.
22. Arnalich F, Maldifassi MC, Ciria E, Codoceo R, Renart J, Fernández-Capitán C, Herruzo R, Garcia-Rio F, López-Collazo E, Montiel C. Plasma levels of mitochondrial and nuclear DNA in patients with massive pulmonary embolism in the emergency department: a prospective cohort study. Crit Care. 2013;17:R90. doi: 10.1186/cc12735.
23. Diaz JA, Fuchs TA, Jackson TO, Kremer Hovinga JA, Lämmle B, Henke PK, Myers DD Jr, Wagner DD, Wakefield TW. Plasma DNA is elevated in patients with deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2013;1:341-348.doi 10.1016/j.jvsv.2012.12.002.
24. Saukkonen K, Lakkisto P, Pettilä V, Varpula M, Karlsson S, Ruokonen E, Pulkki K; Finnsepsis Study Group. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin Chem. 2008;54:1000-1007. doi: 10.1373/clinchem.2007.101030.
25. Moreira VG, Prieto B, Rodríguez JS, Alvarez FV. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem. 2010;47(Pt 3):253-258. doi: 10.1258/acb.2010.009173.
26. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34:1977-1984. doi: 10.1161/ATVBAHA.114.304114.
27. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318-1321. doi: 10.1038/nm.2053.
28. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187:2626-2631. doi: 10.4049/jimmunol.1003930.
29. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136-144. doi: 10.1111/j.1538-7836.2011.04544.x.
30. Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. J Biol Chem. 2011;286:41949-41962. doi: 10.1074/jbc.M111.301218.
31. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38:15-23. doi: 10.1016/j. transci.2007.12.005.
32. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ. 2003;10:108-116. doi: 10.1038/sj.cdd.4401161.
33. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-1665.
34. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231-241. doi: 10.1083/jcb.200606027.
35. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21:131-142.
36. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000;46:319-323.
37. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9:2313-2321. doi: 10.1111/j.1538-7836.2011.04465.x.
38. Lorente L, Martín MM, Borreguero-León JM, Solé-Violán J, Ferreres J, Labarta L, Diáz C, Jiménez A, Páramo JA. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients. Thromb Res. 2014;134:182-186. doi: 10.1016/j. thromres.2014.04.013.
39. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, Sakata Y. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398-405. doi: 10.1532/IJH97.05190.
40. Dofferhoff AS, Bom VJ, de Vries-Hospers HG, van Ingen J, vd Meer J, Hazenberg BP, Mulder PO, Weits J. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med. 1992;20:185-192.
41. van Deventer SJ, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-2526.
42. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, Agosti JM, Colman RW, Suffredini AF. Activation of the contact and fibrinolytic systems after intravenous administration of endotoxin to normal human volunteers: correlation with the cytokine profile. Immunopharmacology. 1996;33:231-237.
43. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Büller HR, Hack CE, Ten Cate JW. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond). 1995;88:587-594.
44. Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med. 1989;17:724-733.
45. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost. 2001;86:543-549.
46. Nair CH, Shah GA, Dhall DP. Effect of temperature, pH and ionic strength and composition on fibrin network structure and its development. Thromb Res. 1986;42:809-816.
47. Carr ME Jr, Gabriel DA, McDonagh J. Influence of Ca2+ on the structure of reptilase-derived and thrombin-derived fibrin gels. Biochem J. 1986;239:513-516.
48. Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31:e88-e99. doi: 10.1161/ATVBAHA.111.230631.
49. Sasaki S, Noguchi H. Interaction of fibrinogen with dextran sulfate. J Gen Physiol 1959;43:1-12.
50. Varju I, Longstaff C, Szabo L, Farkas ÁZ, Varga-Szabó VJ, Tanka-Salamon A, Machovich R, Kolev K. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. Thromb Haemost 2015;113: 1289-1298. doi: 10.1160/TH14-08-0669.
51. Esmon CT. Molecular circuits in thrombosis and inflammation. Thromb Haemost. 2013;109:416-420. doi: 10.1160/TH12-08-0634.
52. Longstaff C, Varjú I, Sótonyi P, Szabó L, Krumrey M, Hoell A, Bóta A, Varga Z, Komorowicz E, Kolev K. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem. 2013;288:6946-6956. doi: 10.1074/jbc.M112.404301.
53. Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, Gröne HJ, Brinkmann V, Jenne DE. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623-625. doi: 10.1038/nm.1959.
54. Kambas K, Mitroulis I, Ritis K. The emerging role of neutrophils in thrombosis-the journey of TF through NETs. Front Immunol. 2012;3:385:1-8. doi: 10.3389/fimmu.2012.00385.
55. Lu T, Kobayashi SD, Quinn MT, Deleo FR. A NET Outcome. Front Immunol. 2012;3:365. doi: 10.3389/fimmu.2012.00365.
56. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost. 2007;5 Suppl 1:24-31. doi: 10.1111/j.1538-7836.2007.02519.x.
57. Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost. 2007;98:512-520.
58. Sodeinde OA, Sample AK, Brubaker RR, Goguen JD. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun. 1988;56:2749-2752.
59. Meng W, Paunel-Görgülü A, Flohé S, Hoffmann A, Witte I, MacKenzie C, Baldus SE, Windolf J, Lögters TT. Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice. Crit Care. 2012;16:R137. doi: 10.1186/cc11442.
60. Mai SHC, Khan M, Dwivedi DJ, Ross CA, Zhou J, Gould TJ, Gross PL, Weitz JI, Fox-Robichaud AE, Liaw PC. Delayed but not early treatment with DNase reduces organ damage and improves outcome in a murine model of sepsis. Shock 2015;44:166-172.